drug

Sublingual film containing dexmedetomidine (BXCL501)

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by BioXcel Therapeutics Inc

2 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Schizo Affective Disorder Schizophreniform Disorders Agitation Bipolar Disorder Psychomotor Agitation Schizophrenia Bipolar Disorder Psychotic Disorders Schizoaffective Disorder

Trials

Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

NCT05974527Phase 4Withdrawn

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303Phase 3Completed

KOLs & investigators

Robert Risinger, MDKOL score 0

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

BioXcel Therapeutics Inc

company

trial

Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

PHASE4

trial

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

PHASE3

trial

indication

Schizophrenia

indication

Schizo Affective Disorder

indication

Schizophreniform Disorders

indication

Agitation

indication

KOL

Robert Risinger, MD

KOL score 0

person